Rappaport Reiches Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Rappaport Reiches Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$513K	Buy	69,075 +995	+1%	+$7.65K	0.13%	60
2024 Q4	$408K	Hold	68,080	–	–	0.11%	67
2024 Q3	$349K	Hold	68,080	–	–	0.09%	74
2024 Q2	$246K	Hold	68,080	–	–	0.07%	81
2024 Q1	$219K	Hold	68,080	–	–	0.07%	94
2023 Q4	$334K	Hold	68,080	–	–	0.12%	60
2023 Q3	$371K	Hold	68,080	–	–	0.16%	51
2023 Q2	$457K	Hold	68,080	–	–	0.19%	48
2023 Q1	$601K	Hold	68,080	–	–	0.27%	40
2022 Q4	$520K	Hold	68,080	–	–	0.26%	42
2022 Q3	$485K	Hold	68,080	–	–	0.25%	41
2022 Q2	$551K	Hold	68,080	–	–	0.28%	40
2022 Q1	$945K	Hold	68,080	–	–	0.5%	28
2021 Q4	$1.91M	Sell	68,080 -65,250	-49%	-$2M	1.64%	12
2021 Q3	$4.53M	Hold	133,330	–	–	4.48%	4
2021 Q2	$5.45M	Buy	+133,330	New	+$5.18M	5.73%	3

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rappaport Reiches Capital Management's ADPT Position: Q1 2025 in Review

Rappaport Reiches Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 1.5% in Q1 2025, buying an estimated $7.65K and bringing the position to 69,075 shares worth $513K. The position accounts for 0.13% of the portfolio, ranked #60.

Rappaport Reiches Capital Management first reported a position in ADPT in Q2 2021 and has held it in 16 quarters since. The position peaked at $5.45M in Q2 2021. 225 funds tracked by Wall St. Rank hold ADPT as of Q1 2025.

Rappaport Reiches Capital Management held 69,075 shares of Adaptive Biotechnologies worth $513K as of Q1 2025.
Rappaport Reiches Capital Management bought 995 Adaptive Biotechnologies shares in Q1 2025, an estimated $7.65K.
Adaptive Biotechnologies made up 0.13% of Rappaport Reiches Capital Management's portfolio in Q1 2025, its #60 holding.
Rappaport Reiches Capital Management first reported a position in Adaptive Biotechnologies in Q2 2021 and has held it in 16 quarters since.
Rappaport Reiches Capital Management's Adaptive Biotechnologies position peaked at $5.45M in Q2 2021.
225 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2025.

Based on Rappaport Reiches Capital Management's 13F filing for Q1 2025, filed 22 Apr 2025.